An IFN-y-Integrin-Growth Factor Axis in GA Biomarker Development
GA 生物标志物开发中的 IFN-γ-整合素生长因子轴
基本信息
- 批准号:7297628
- 负责人:
- 金额:$ 36.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-01 至 2011-08-31
- 项目状态:已结题
- 来源:
- 关键词:SCID mouseT lymphocyteangiocardioultrasonographyarteriosclerosisbiomarkerblood vessel transplantationcell differentiationcell migrationdelayed hypersensitivitygrowth factor receptorsheart transplantationhuman subjecthypoxiainterferon gammamolecular pathologymonocyteneuropilinspathologic processpatient oriented researchtissue /cell culturetissue mosaicismtransplant rejectionvascular endothelial growth factorsvascular endothelium
项目摘要
The hallmark of graft arteriosclerosis (GA) is vascular remodeling, which includes intimal and medial
expansion by matrix deposition and medial smooth muscle cell (VSMC) proliferation with migration into the
neointima. Interferon-gamma (IFN-y) plays a causative and key role in immune-mediated remodeling
responses typical of those observed in GA. Our cDNA array and immunohistochemical analyses of
arteriopathic, explanted human allograft coronary vessels identified vascular endothelial growth factor
receptor-2 (VEGFR2) and Neuropilin-2, both VEGF-responsive receptors, and endothelial/smooth muscle
cell-derived neuropilin-like molecule (ESDN), as potential specific GA markers. Because of the known
VEGFR2-alpha-v--beta3 interactions and the role of alpha-v-beta3 in VSMC migration/proliferation, we utilized the chimeric human arterial transplant/SCID mouse model of GA to address whether alpha-v-beta3 is modulated during GA. We demonstrated that alpha-v-beta3, ESDN and VEGFR2 are all highly upregulated and/or activated as early events in GA, consistent with cell proliferation kinetics. VEGF can induce Th1 cell polarization and activate alpha-v-beta3
integrin. alpha-v-beta3 engagement can, in turn, enhance VEGFR2-mediated signaling. We hypothesize that VEGF,
induced by tissue hypoxia and/or alloreactivity, contributes to T cell differentiation, IFN-y elaboration and
consequent DTH-like responses. In parallel, VEGF, through its classical receptors and neuropilin-like
molecules, modulates VSMC integrin activation and alpha-v-beta3-mediated cell proliferation/migration, a hallmark
feature of GA. Specific proposals now include to: (1) determine whether VEGF contributes to the
development of IFN-y- producing T cells and GA utilizing VEGF/VEGFR antagonists in the chimeric SCID
mouse/human arterial graft model, and in allogeneic T cell-endothelial cell cultures; (2) assess the causative
role of alpha-v-beta3 integrin activation/function in allogeneic peripheral blood mononuclear cell (PBMC)- and IFN-y-induced GA and its relationship to IFN-yR and VEGFR signaling, using the SCID/human arterial transplant
model and alpha-v-beta3 antibody-mediated blockade, as well as in vivo GA imaging with an activated alpha-v-beta3-targeted agent and microSPECT technology; (3) determine whether ESDN induction in GA is IFN-y-mediated or
VEGF-dependent, utilizing the allogeneic human PBMC or IFN-y stimuli in the chimeric mouse model, and
whether ESDN expression enhances or terminates maximal GA responses; and (4) address the IFN-y-
VEGFR/ESDN-alpha- v-beta3 axis in cardiac transplant patients, correlating intravascular ultrasound- documented GA
with microvessel-localized IFN-y, IFN-y-regulated chemokines, VEGF/VEGFRs, alpha-v-beta3 and ESDN expression
in endomyocardial biopsy specimens and, for secreted molecules, serum samples. Molecular mechanisms
of the pathways identified in vivo in Aims 1-3 will be studied in vitro, and relevance to human GA will be
addressed in Aim 4. The proposed studies will establish the validity of an IFN-y - alpha-v-beta3 - VEGFR/ESDN axis in
the development of GA, thus defining sensitive and practical markers of early GA.
移植物动脉硬化(GA)的标志是血管重塑,包括内膜和中膜的重塑。
通过基质沉积和中膜平滑肌细胞(VSMC)增殖并迁移到
新生内膜干扰素-γ(IFN-γ)在免疫介导的重塑中起着重要的作用
在GA中观察到的典型反应。我们的cDNA阵列和免疫组织化学分析,
动脉病性、移植的人同种异体冠状血管鉴定出血管内皮生长因子
受体-2(VEGFR 2)和神经纤毛蛋白-2(Neuropilin-2),两者均为VEGF反应性受体,以及内皮/平滑肌
细胞源性神经纤毛蛋白样分子(ESDN),作为潜在的特异性GA标志物。由于已知的
VEGFR 2-α-v-β 3相互作用和α-v-β 3在VSMC迁移/增殖中的作用,我们利用GA的嵌合人动脉移植/SCID小鼠模型来解决α-v-β 3在GA期间是否受到调节。我们证明,α-v-β 3,ESDN和VEGFR 2都是高度上调和/或激活的早期事件在GA,符合细胞增殖动力学。VEGF可诱导Th 1细胞极化,激活α-v-β 3
整联蛋白α-v-β 3结合反过来可以增强VEGFR 2介导的信号传导。我们假设VEGF,
由组织缺氧和/或同种异体反应性诱导的IFN-γ,有助于T细胞分化、IFN-γ加工和
类似DTH的反应。与此同时,VEGF通过其经典受体和神经纤毛蛋白样受体,
分子,调节VSMC整合素活化和α-v-β 3介导的细胞增殖/迁移,这是VSMC整合素活化的标志。
GA的特点。目前的具体建议包括:(1)确定VEGF是否有助于
在嵌合SCID中开发利用VEGF/VEGFR拮抗剂的产生IFN-γ的T细胞和GA
小鼠/人动脉移植物模型和同种异体T细胞-内皮细胞培养物中;(2)评估
α-v-β 3整合素活化/功能在同种异体外周血单核细胞(PBMC)和IFN-γ诱导的GA中的作用及其与IFN-γ R和VEGFR信号传导的关系,使用SCID/人动脉移植
模型和α-v-β 3抗体介导的阻断,以及用活化的α-v-β 3靶向剂和microSPECT技术的体内GA成像;(3)确定GA中的ESDN诱导是IFN-γ介导的还是
VEGF依赖性,在嵌合小鼠模型中利用同种异体人PBMC或IFN-γ刺激,和
ESDN表达是否增强或终止最大GA应答;和(4)解决IFN-γ-γ-IFN-γ的表达。
心脏移植患者中的VEGFR/ESDN-alpha- v-beta3轴,与血管内超声相关-记录的GA
微血管定位的IFN-γ、IFN-γ调节的趋化因子、VEGF/VEGF受体、α-v-β 3和ESDN表达
在肌内膜活检标本中,对于分泌分子,在血清样品中。分子机制
将在体外研究目标1-3中体内鉴定的途径,并将研究与人GA的相关性。
在目标4中。拟议的研究将确立IFN-γ-α-v-β 3- VEGFR/ESDN轴在
GA的发展,从而确定敏感和实用的早期GA标记。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY R. BENDER其他文献
JEFFREY R. BENDER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY R. BENDER', 18)}}的其他基金
IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF)
IL-17A mRNA 靶向寡核苷酸治疗特发性肺纤维化 (IPF)
- 批准号:
10761365 - 财政年份:2023
- 资助金额:
$ 36.37万 - 项目类别:
Immune cell skewing with RNA target site oligonucleotides to promote vascular smooth muscle cell homeostasis
RNA靶位点寡核苷酸倾斜免疫细胞促进血管平滑肌细胞稳态
- 批准号:
10593490 - 财政年份:2022
- 资助金额:
$ 36.37万 - 项目类别:
microRNA target site RNA-directed oligonucleotide topical therapeutics in psoriasis
microRNA 靶位点 RNA 引导的寡核苷酸局部治疗银屑病
- 批准号:
10287633 - 财政年份:2021
- 资助金额:
$ 36.37万 - 项目类别:
microRNA target site RNA-directed oligonucleotide topical therapeutics in psoriasis
microRNA 靶位点 RNA 引导的寡核苷酸局部治疗银屑病
- 批准号:
10426347 - 财政年份:2021
- 资助金额:
$ 36.37万 - 项目类别:
Competitive macrophage microRNA-RNA binding protein interactions in wound repair
伤口修复中竞争性巨噬细胞 microRNA-RNA 结合蛋白相互作用
- 批准号:
9439844 - 财政年份:2017
- 资助金额:
$ 36.37万 - 项目类别:
Competitive macrophage microRNA-RNA binding protein interactions in wound repair
伤口修复中竞争性巨噬细胞 microRNA-RNA 结合蛋白相互作用
- 批准号:
10001549 - 财政年份:2017
- 资助金额:
$ 36.37万 - 项目类别:
Modulation neuroinflammation through interference of cooperative microRNA-RNA-binding protein interactions
通过干扰 microRNA-RNA 结合蛋白相互作用来调节神经炎症
- 批准号:
9300853 - 财政年份:2016
- 资助金额:
$ 36.37万 - 项目类别:
An IFN-y-Integrin-Growth Factor Axis in GA Biomarker Development
GA 生物标志物开发中的 IFN-γ-整合素生长因子轴
- 批准号:
7491183 - 财政年份:2007
- 资助金额:
$ 36.37万 - 项目类别:
Imaging DTH, IFN gamma responses & GA in human arteries
成像 DTH、IFN γ 反应
- 批准号:
6659332 - 财政年份:2002
- 资助金额:
$ 36.37万 - 项目类别:
相似海外基金
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
$ 36.37万 - 项目类别:
Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
$ 36.37万 - 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
$ 36.37万 - 项目类别:
University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
$ 36.37万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
$ 36.37万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
$ 36.37万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574978-2022 - 财政年份:2022
- 资助金额:
$ 36.37万 - 项目类别:
University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
$ 36.37万 - 项目类别:
Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
- 批准号:
RGPIN-2015-05491 - 财政年份:2021
- 资助金额:
$ 36.37万 - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
- 批准号:
RGPIN-2019-06980 - 财政年份:2021
- 资助金额:
$ 36.37万 - 项目类别:
Discovery Grants Program - Individual